\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesThe second wave of calls under the Digital Europe programme have been published on the Funding & Tenders Portal. The calls will open on 22 February and close on 17 May 2022.
The 17 call topics include among others Testing & Experimentation Facilities for Agrifood, Health, Manufacturing and Smart Cities & Communities, different sectoral data spaces, cybersecurity, education & training, blockchain, and different deployment actions.
On 23 February, NCP and the Department of Economics, Science & Innovation (Departement EWI) jointly organise an info session to inform about the content of the upcoming calls, requirements to participate in the programme and the support NCP Flanders can give to interested stakeholders.
Users of the NCP Flanders website interested in receiving more tailor-made information depending on individual interests are strongly encouraged to update their profile and indicate individual thematic blocks to receive specific information on their field of interest.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
